文献速递精神分裂症与精神病性障碍心境障碍

重现精神分裂症多巴胺病理生理及改善方法:氯胺酮转化影像研究

Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine.
PubMed 文献 · Mol Psychiatry · 2020-05-07

该研究在小鼠中采用亚慢性氯胺酮处理,建立类似精神分裂症纹状体多巴胺合成能力增高的转化模型。亚慢性氯胺酮使纹状体多巴胺合成能力(Cohen's d=2.5)和 locomotor activity 增加,抑制中脑多巴胺神经元或激活前肢皮质和腹侧海马 PV 中间神经元可逆转这些效应。SEP-363856(TAAR1/5-HT1A 激动剂)显著减少氯胺酮诱导的多巴胺合成能力增加。

要点

  • 亚慢性氯胺酮小鼠再现精神分裂症纹状体多巴胺合成能力增高。
  • 抑制中脑多巴胺神经元或激活皮质/海马 PV 中间神经元可逆转该效应。
  • TAAR1/5-HT1A 激动剂 SEP-363856 减轻氯胺酮诱导的多巴胺合成增加。

核心结论

  • 亚慢性氯胺酮处理小鼠可模拟精神病患者的多巴胺能改变,该改变依赖中脑多巴胺神经元激活,并可通过激活 PV 中间神经元或 TAAR1/5-HT1A 激动剂改善。

研究设计与样本

  • 小鼠接受亚慢性氯胺酮(30 mg/kg)或生理盐水处理,后进行纹状体多巴胺合成能力的在体 PET 成像。
  • 采用旷场实验测量 locomotor activity,并使用在体细胞类型特异性化学遗传学方法和药理学干预操纵神经元兴奋性。
  • 采用免疫组织化学和 RNA 测序探究分子机制。

主要发现

  • 亚慢性氯胺酮增加纹状体多巴胺合成能力(Cohen's d=2.5)和 locomotor activity。
  • 抑制中脑多巴胺神经元、激活前肢皮质和腹侧海马 PV 中间神经元可抵消上述效应。
  • 亚慢性氯胺酮降低这些皮质和海马区域的 PV 表达。
  • SEP-363856 显著减少氯胺酮诱导的多巴胺合成能力增加。

关键数值与推荐

  • 亚慢性氯胺酮剂量为 30 mg/kg。
  • 纹状体多巴胺合成能力增加的效应量为 Cohen's d=2.5。
  • SEP-363856 对 trace amine receptor 1(TAAR1)和 5-HT1A 受体有激动作用,对多巴胺 D2 受体无明显作用。

临床怎么用

  • 提示激活 PV 中间神经元或使用 TAAR1/5-HT1A 激动剂可能靶向精神分裂症突触前多巴胺功能异常。
  • 氯胺酮对多巴胺系统的影响与氯胺酮治疗重性抑郁的效应相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with schizophrenia show increased striatal dopamine synthesis capacity in imaging studies. The mechanism underlying this is unclear but may be due to N-methyl-D-aspartate receptor (NMDAR) hypofunction and parvalbumin (PV) neuronal dysfunction leading to disinhibition of mesostriatal dopamine neurons. Here, we develop a translational mouse model of the dopamine pathophysiology seen in schizophrenia and test approaches to reverse the dopamine changes. Mice were treated with sub-chronic ketamine (30 mg/kg) or saline and then received in vivo positron emission tomography of striatal dopamine synthesis capacity, analogous to measures used in patients. Locomotor activity was measured using the open-field test. In vivo cell-type-specific chemogenetic approaches and pharmacological interventions were used to manipulate neuronal excitability. Immunohistochemistry and RNA sequencing were used to investigate molecular mechanisms. Sub-chronic ketamine increased striatal dopamine synthesis capacity (Cohen's d = 2.5) and locomotor activity. These effects were countered by inhibition of midbrain dopamine neurons, and by activation of PV interneurons in pre-limbic cortex and ventral subiculum of the hippocampus. Sub-chronic ketamine reduced PV expression in these cortical and hippocampal regions. Pharmacological intervention with SEP-363856, a novel psychotropic agent with agonism at trace amine receptor 1 (TAAR1) and 5-HT1A receptors but no appreciable action at dopamine D2 receptors, significantly reduced the ketamine-induced increase in dopamine synthesis capacity. These results show that sub-chronic ketamine treatment in mice mimics the dopaminergic alterations in patients with psychosis, that this requires activation of midbrain dopamine neurons, and can be ameliorated by activating PV interneurons and by a TAAR1/5-HT1A agonist. This identifies novel therapeutic approaches for targeting presynaptic dopamine dysfunction in patients with schizophrenia and effects of ketamine relevant to its therapeutic use for treating major depression.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kokkinou M, Irvine EE, Bonsall DR, et al. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. Mol Psychiatry. 2020. PMID: 32382134. doi:10.1038/s41380-020-0740-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。